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R&D Delegation in a Duopoly with Spillovers
Abstract
There is evidence that competing firms delegate R&D to the same independent profit-maximizing
laboratory. We draw on this stylized fact to construct a model where two firms in the same industry
offer transfer payments in exchange of user-specific R&D services from a common laboratory. Inter-
firm and within-laboratory externalities affect the intensity of competition among delegating firms on
the intermediate market for technology. Whether competition is relatively soft or tight is reflected
by each firm’s transfer payment offers to the laboratory. This in turn determines the laboratory’s
capacity to earn profits, R&D outcomes, delegating firms’ profits, and social welfare. We compare the
delegated R&D game to two other ones where firms (i) cooperatively conduct in-house R&D, and (ii)
non-cooperatively choose in-house R&D. The delegated R&D game Pareto dominates the other two
games, and the laboratory earns positive profits, only if within-laboratory R&D services are sufficiently
complementary but inter-firm spillovers are sufficiently low. We find no room for policy intervention,
because the privately profitable decision to delegate R&D, when the laboratory participates, always
benefits consumers.
JEL Classification: C72; L13; O31.
Keywords: Research and Development, Externalities, Common agency.
1 Introduction
Examples of firms delegating (i.e. outsourcing) R&D to for-profit laboratories abound. The National
Science Foundation (2006) indicates that “[t]he average [real] annual growth rate of contracted-out
R&D from 1993 to 2003 (9.4%) was about double the growth rate of in-house company-funded R&D
(4.9%). For manufacturing companies, contracted-out R&D grew almost three times as fast as R&D
performed internally, after adjusting for inflation.”1 Chemical companies are at the forefront of this
phenomenon. They report $2.8 billon in contracted-out R&D in 2003, of which $2.7 billion were for
pharmaceuticals and drugs. More surprising is the fact that rival firms often delegate their R&D to
a common independent laboratory. For example, Bayer and ICI (two European firms in the chemical
industry which compete on world markets) signed multi-year contracts in 1999 and 2000 respectively
with Symyx, a U.S.-based private laboratory. Symyx receives payments by providing access to a
proprietary technology for the production of high-value specialty polymers. Similar arrangements are
observed in other sectors. In the steel industry, for example, ThyssenKrupp and Arcelor (two major
European suppliers), contracted in 1995 with VAI, a laboratory which specializes in the design of new
steel production methods. The R&D services received from VAI aim at producing wide thin strips
of stainless and carbon steel directly from the molten metal, omitting the stages of slab casting and
rolling.
There is evidence that firms which delegate their R&D to an independent laboratory place restric-
tions on the uses of the research. R&D contracts typically state the targeted outcome in exchange of
a payment scheme which specifies either discriminatory clauses where rival firms are listed or exclu-
sivity conditions. Such conditions include the right of first refusal, whereby the contracting firm can
purchase the rights to specific R&D outcomes before anyone else, or a veto power over the ability of
the laboratory to offer a license to any other party. For example, restrictions of this kind appear in a
1997 contract between Millennium (a U.S.-based private laboratory in the biotechnology sector) and
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Monsanto (a US provider of agricultural products) for gene-sequencing R&D services. In this contract,
Millennium agrees not to make any other significant agricultural enterprise benefit from the outcomes
collaboration, in the near future (i.e., for an agreed-upon period of time), unless Monsanto has given its
written consent. Rival firms may also place clauses that refer explicitly to each other in R&D contracts,
in order to restrict who might get access to a common laboratory’s output. For example, a 1998 R&D
contract between Millennium and a pharmaceutical division of Bayer stipulates that the firm may not
benefit from the output of existing bilateral collaborative research agreements signed in the past by
the laboratory and a list of competitors, including Hoffmann-La Roche, Eli Lilly, and Pfizer.2
In most cases, independent laboratories do provide information on the content of the contracts they
sign, and on the identity of the firms they serve, in order to signal the relevance of their technological
skills to potential clients. This information is very often supplied through press releases or on the web
sites of the laboratories.
We draw from these industry practices to construct a game where firms may delegate R&D to an
independent laboratory. We compare the outcomes of this game with two other ones where R&D is
conducted in-house either cooperatively or non-cooperatively. We allow firm-specific R&D services to
be either complements, substitutes, or independent inside the laboratory’s R&D cost function. We (i)
ask when the laboratory earns positive profits, (ii) compare R&D outcomes, firms’ profits, and social
welfare in a delegated game with those in cooperative and non-cooperative in-house R&D games, and
(iii) derive conditions for R&D delegation to Pareto-dominate cooperative and non-cooperative R&D.
While we know of no theoretical model of R&D delegation to a common laboratory, even though such
contracts are common, there is an extensive literature on the supply of technology licenses and in-house
R&D. The literature on licenses typically considers a monopolistic laboratory which sells a patented
process innovation to vertically-related firms by making take-it-or-leave-it offers to downstream firms.
Most analyses build on Katz and Shapiro’s (1986) complete information model where the laboratory
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incurs no cost (i.e., R&D costs have been paid in a previous period), and each downstream firm is a
potential user of one unit of the innovative input.3 These analyses base an inventor’s ability to earn
benefits on the strategic interaction among potential licensees.
The in-house R&D literature pays particular attention to how technological spillovers affect R&D
outcomes, firms’ profits, and social welfare, when firms may choose R&D cooperatively or non-cooperatively.
In their seminal analysis, d’Aspremont and Jacquemin (1988) consider duopolistic firms which invest
in deterministic cost-reducing R&D. They show that cooperation is R&D augmenting and welfare im-
proving when between-firm technological spillovers are sufficiently high. The numerous extensions to
their model assume in-house R&D, either in each firm’s separate laboratory or in a jointly owned one,
with firms sharing the operating costs.4 Amir, Evstigneev and Wooders (2003) unify and generalize
the results of this literature without relying on specific functional forms. They confirm two central
results of this research stream: (i) R&D cooperation increases firms’ profits; and (ii) the profitability
of R&D cooperation increases with the level of R&D spillovers.5
As in d’Aspremont and Jacquemin (1988), we set up a model where two symmetric firms behave a`
la Cournot on a final market and benefit from cost-reducing R&D outputs. We build on this benchmark
framework by giving firms the option to delegate R&D non-cooperatively to an independent laboratory.
As in Katz and Shapiro (1986), the laboratory is a profit-maximizer, and may serve none, one, or two
firms. However, we abandon their assumption that the laboratory sells at no cost, and as a price
maker, the fruit of past R&D efforts. Rather, we assume the laboratory responds to payment schemes
by providing firm-specific R&D services at some costs.6 This assumption captures situations where a
laboratory derives income from tailor-made R&D which it provides to firms.
We consider that R&D generates two externalities: (i) the usual between-firm cost-reducing tech-
nological spillovers, and (ii) positive or negative within-laboratory externalities depending on whether
R&D services are complements or substitutes. We refer to the first externalities as direct externalities
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and to the second as indirect ones. We allow firm-specific R&D services to be either complements or
substitutes in the laboratory, i.e. indirect externalities can be positive or negative respectively.7 We
use the natural ability of the common agency framework to capture the antagonistic action of two
forces: (i) the congruent objectives of the two users to share the resources of the same laboratory
so as to benefit from economies of scope, and (ii) the competing attempts by each firm to pull the
production of R&D services towards its individual needs. In this model, we assume the laboratory (an
agent) may accept the contracts offered by the two firms (principals), or only one firm, or none. To
capture the large contracting possibilities observed in real-world contracts, we also specify that each
firm may observe and verify the R&D services delivered to its rival.
Using the terminology introduced by Bernheim and Whinston (1986a), we construct a delegated
common agency model. This means that the agent may accept only a subset of contracts.8 Our
common agency model is also of the public kind, a definition which appears in Martimort (2005). This
says that each principal may observe and verify the level of output which is delivered to the other
principal, and thus condition its payment scheme on it.9
We establish a number of interesting and novel results. This is done by investigating the effect of
harmonized or conflicting requirements by R&D users, as a function of direct and indirect externalities,
on the ability of firms and the laboratory to earn more benefits than in alternative options. This leads
to identify the situations in which the laboratory finds it profitable to deliver R&D services not only
to one firm, but to both of them. In the latter case, while one could expect the laboratory to always
earn positive benefits when R&D services demanded by the firms are complements, we prove this is
not the case. We find that the laboratory earns positive benefits only if the firm-specific R&D services
it produces are substitutable, or not too complementary, and inter-firm spillovers are sufficiently low.
Intuitively, the ability of the laboratory to earn positive benefits depends on the degree of rivalry
between the two firms for its services. This rivalry is a function of the degree of the complementarity or
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substitutability of the research projects inside the laboratory (indirect externalities) and of inter-firm
spillovers (direct externalities). On the one hand, if the R&D services are rival, in the sense that the
marginal cost of supplying one firm increases with the level of R&D supplied to the other firm, then
the two firms will compete for the laboratory’s services. This effect is reinforced by a sufficiently low
level of spillovers, implying that the R&D output received by a firm yields benefits almost exclusively
to itself. On the other hand, if the R&D services which the two firms purchase from the laboratory
are complements, then they benefit from each other’s projects and are thus not inclined to ask for
exclusive services from the laboratory. A sufficiently high degree of inter-firm spillovers has a similar
effect because in this case each firm benefits substantially from the R&D services received by the other
player. Either one of the two effects may dominate. When the combination of direct and indirect
externalities is positive each firm is interested in seeing the other one contract also. In this case,
competition for the control of laboratory’s choices is soft. This is unfavorable to the laboratory. When
combined direct and indirect externalities are negative, competition for the control of R&D services
supplied by the laboratory is tight, a situation which is favorable to the laboratory. Eventually, whether
competition for the laboratory’s services is soft or tight is reflected by each firm’s payment offers to
the laboratory, and hence drives the ability of the latter to earn excess benefits. Finally, if research
projects are extremely substitutable, the laboratory finds it profitable to serve one firm only.
In more technical terms, we are able to partition the space of indirect and direct externalities
into two subspaces. In the first one the laboratory exactly breaks even, whereas in the second one the
laboratory earns positive benefits. This result is robust to changes in the specific functional forms we use
in the model. Although the algebraic expression of the frontier separating the two subspaces depends
on the linear demand and constant marginal cost which we borrow from the standard R&D literature,
the partition of the externalities space can be obtained with other cost and demand functions. This
is demonstrated by Billette de Villemeur and Versaevel (2004), who propose mild sufficient conditions
on the algebraic form of the laboratory’s cost function, and of firms’ gross profit functions, for either
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negative or positive externalities in R&D dimensions to dominate, and therefore for the laboratory to
earn or not benefits.10
Beyond this preliminary result, the comparison of the delegated R&D game with the two benchmark
games depends on the specific form of the cost and demand functions. This does not mean that
qualitatively similar findings may not be obtained with alternative specifications (for example, by
assuming that R&D inputs are chosen in lieu of outputs, or that firms compete in prices instead of
quantities on the final market). To our knowledge, this still remains to be checked on a case by case
basis for a detailed comparison of R&D levels, firms’ profits, and welfare outcomes in the three games.
Equilibrium R&D in the non-cooperative game is known to be lower (higher) than in the cooperative
setting for high (low) direct spillovers (d’Aspremont and Jacquemin 1988). We show that R&D is
greater (smaller) in the delegated game than in the cooperative one for positive (negative) indirect
spillovers. This occurs because the laboratory internalizes the strategic interaction of the two firms on
the intermediate market for technology and on the final market for products via the payment schemes
it receives. As a result the laboratory’s choice of R&D is equivalent to it maximizing the sum of
its benefits and the two firms’ profits. In particular, zero within-laboratory externalities mean the
equilibrium outcomes of the delegated R&D and cooperative R&D games are identical. When firms
delegate R&D, the complementarity of their research projects means that the laboratory can produce
R&D more efficiently than the firms. Hence, R&D in the delegated game can exceed the non-cooperative
solution even when direct externalities are negative – in which case R&D in the non-cooperative game
exceeds that in the cooperative one – provided indirect externalities are sufficiently positive. For similar
reasons delegated R&D may exceed the non-cooperative solution when direct externalities are positive
provided indirect externalities are not too negative.
When firms delegate R&D to the laboratory, they earn higher profits as indirect externalities
increase. This arises because (i) it is relatively cheaper for the laboratory to perform R&D, than for
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firms to conduct it in house, as indirect externalities increase, while (ii) simultaneously the increased
complementarity between the firms’ R&D services means they can reduce their transfer payments to
the laboratory. We show that firms’ profits are higher when they delegate R&D to the laboratory, than
in the other two organizational forms, for sufficiently high indirect externalities.
However, for reasons given above, there is no guarantee that the laboratory will choose to operate at
such high levels of indirect externalities. If the laboratory must earn positive benefits to participate, the
firms choose to delegate R&D only when direct externalities are low. This result differs sharply from
the well established claim that R&D cooperation (as opposed to delegation) becomes more profitable
with increasingly high direct externalities.
The welfare analysis proceeds by observing that higher R&D implies lower prices, more consump-
tion, and consequently higher consumer surplus. We find that R&D delegation Pareto-dominates
cooperation and non-cooperation, and the laboratory earns positive benefits, if and only if R&D ser-
vices are sufficiently complementary inside the laboratory and inter-firm spillovers are sufficiently low.
This occurs because (i) the laboratory operates only for sufficiently low indirect externalities, whereas
(ii) firms earn higher profits and consumers obtain more surplus with delegated R&D than in the other
two settings only for sufficiently high indirect externalities. This opposition prevents at least one of the
parties (the laboratory, the firms, or consumers) to gain strictly more in the delegated R&D game than
in the other two games when spillovers are too high. From a policy perspective, we prove that a firm’s
choice to delegate R&D to an independent profit-making laboratory never harms consumers. Hence,
there is no room for policy intervention when R&D delegation takes place along the lines described in
this paper.
The present analysis complements those on the industrial organization of R&D, in the spirit
of Aghion and Tirole (1994) and Ambec and Poitevin (2001), which examine the impact of non-
deterministic R&D on the relative efficiency of a separate governance structure (where a single user
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buys an innovation from an independent unit) and an integrated structure (in which the user sources
R&D internally). Both Aghion and Tirole (1994) and Ambec and Poitevin (2001) assume a unique
R&D user. We, on the other hand, are interested in the strategic interaction of several firms which
not only contract with a common laboratory but also compete on the product market.11 Another
more recent strand of the R&D literature analyzes cooperative R&D in vertically-related industries
(Banerjee and Lin 2001, Banerjee and Lin 2003, Atallah 2002, Brocas 2003, Ishii 2004, for examples).
In these papers, firms may benefit from imperfectly appropriable process R&D produced not only by
a direct competitor, but also by upstream or downstream firms. What is transacted by firms between
successive stages of production is an homogeneous input to be transformed in some final good, not
R&D services. Although this framework is perfectly valid for some settings, the examples provided
here concern the delegation of R&D services.
The remainder of the paper is as follows. Section 2 presents the three R&D games, defines and
discusses the equilibrium concepts. Section 3 establishes that the laboratory maximizes aggregate
benefits and derives conditions under which it earns zero benefits. Section 4 ranks the outcomes of
the three R&D games as a function of firm-level technological spillovers and within-laboratory (anti-
)complementarities, and illustrate the results graphically in the direct and indirect externalities plane.
Next, section 5 investigates whether one of the three games can Pareto-dominate the other two and
discusses policy implications. Finally, section 6 concludes. All proofs and figures are in the Appendix.
2 R&D Games
We consider a duopoly which faces a linear inverse demand function:
pi(q) = a− b(qi + θqj), (1)
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for i, j = 1, 2, i 6= j, where q ≡ (qi, qj) ∈ R
2
+ describes output quantities, pi is firm i’s unit price, a
and b are positive parameters, and θ ∈ [0, 1] captures the degree of substitutability between the two
products. Each firm incurs a constant unit cost of production which it can reduce through process
innovations. We also assume, as in d’Aspremont and Jacquemin (1988), a unit cost of production:
ci(x) = c− xi − βxj , (2)
for i, j = 1, 2, i 6= j, where x ≡ (xi, xj) ∈ R
2
+ is the vector of R&D outputs obtained by firms, the
marginal cost parameter c ∈ (0, a), and β ∈ [0, 1] denotes technological spillovers. It follows that firm
i’s gross profit function is:
pii(q,x) = [pi(q)− ci(x)]qi. (3)
The next section formalizes three cost-reducing R&D games in extensive forms.
2.1 Cooperative R&D
In a first stage, the duopoly cooperatively chooses in-house R&D outcomes in the two proprietary





for i = 1, 2, and where γ is a positive parameter. In a second stage, given the chosen R&D outcomes
each firm non-cooperatively maximizes individual profits by choosing its output. We solve this game
by backward induction. We start with stage two by looking for the Nash equilibrium in quantities on
the final market.
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Definition 1 (NE) The symmetric final market outcome q∗(x) is a Nash equilibrium if:
pii(q
∗(x),x) ≥ pii(qi, q
∗
j (x),x), (5)
all x and all qi, i, j = 1, 2, i 6= j.
Substituting q∗(x) into the gross profit equation (3), we define firm i’s concentrated profits as
pii(x) ≡ pii(q
∗(x),x). This last expression describes gross profits where a firm behaves a` la Cournot on
the final market for all levels of R&D. Using this concentrated profits function, we can express firm i’s
net profits in the first stage of the game, as a function of x, by:
pici (x) ≡ pii(q
∗(x),x)− r(xi). (6)
We then maximize the sum of the two firms’ profits to obtain the symmetric equilibrium level of
R&D, denoted by xc.12 Substituting xc ≡ (xc, xc) in (6) we can calculate a firm’s symmetric net
equilibrium profits as pic = pici (x
c). The vector of output quantities in the cooperative game is obtained
by evaluating q∗ at xc, denoted by qc.
Instead of cooperatively choosing their R&D, firms may decide to do so non-cooperatively, as
explained below.
2.2 Non-Cooperative R&D
In a first stage, firms non-cooperatively conduct R&D in-house by maximizing their individual profits
in their own R&D, with each firm’s R&D costs given by (4). The second stage is as in the cooperative
R&D game. In this game, we denote firm i’s net profit as a function of x by:
pini (x) ≡ pii(q
∗(x),x)− r(xi). (7)
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We solve the game by backward induction.
Definition 2 (SPNE) The symmetric equilibrium quantities and in-house R&D outcomes (qn,xn)
are a subgame-perfect Nash equilibrium if:
i) qn ≡ q∗(xn), where q∗(x) is a NE as in Definition 1;
ii) xn is a NE, that is pini (x
n) ≥ pini (xi, x
n
j ), for all xi, i, j = 1, 2, i 6= j.
Substituting xn into (7) we obtain each firm’s symmetric net equilibrium profits, denoted by pin.
This game is identical to another one where, in lieu of in-house R&D production, there are two
independent laboratories. In that alternative game, each firm writes a contract with a dedicated
laboratory to obtain specific R&D services in exchange of transfer payments. This gives two symmetric
principal-agent relationships. It follows that a firm’s problem is as in (7), but r(xi) is now firm i’s
payment for xi, in lieu of an R&D cost. In a complete information set-up, if each laboratory must
at least break even to participate, each firm’s payment can be chosen so that each laboratory earns
exactly zero benefits. 13 The problem is however different if there is a unique, common, and independent
laboratory, from which the two firms buy R&D services. We tackle this next in a new framework.
2.3 Delegated R&D
We assume there is one independent laboratory which produces R&D at a cost which increases with the
quantity supplied to each firm. However, within-laboratory externalities can arise when the laboratory
produces R&D for both firms. The sign of externalities depends on the nature of the R&D services
which the firms request. The production of R&D services is said to be complementary (substitutable)
when the marginal cost of supplying one firm decreases (increases) with the quantity supplied to the
other firm.
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For the sake of tractability, and comparison with the numerous cooperative and non-cooperative
R&D games explored in the literature using the framework of d’Aspremont and Jacquemin (1988), we







for i = 1, 2 and i 6= j, and δ ∈ [−γ, γ). The parameter δ captures complementary (substitutable) R&D
services in the laboratory if it is positive (negative). If δ equals zero, the laboratory is as efficient as
each firm’s proprietary laboratory and (8) collapses to the sum of (4) over the two firms. Note that the
term δx1x2 is the simplest way to capture complementarity or substitutability between two variables.
A nice aspect of (8) is that complementarity or substitutability is reflected by the sign of a single
parameter as suggested by Milgrom and Roberts (1990, p. 517) in an illustrative example. The same
algebraic specification appears in the complete information version of the cost function of a common
agent in Martimort and Stole (2003a), and in the utility function of a common agent in Martimort and
Stole (2003b).
In the delegated R&D game, we let each firm’s transfer to the laboratory depend on both its R&D,
and that of its competitor, purchased from the laboratory. Formally, we denote for each firm the set
of transfer payments by:
T ≡ {t|t(x) ≥ 0 for all x}. (9)
This specification differs from much of the common agency literature which usually focuses on
the consumer goods market where each principal supplies a common agent which is a retailer or a
consumer (Gal-Or 1991, Stole 1991, Martimort 1996, Bernheim and Whinston 1998, Calzolari and
Scarpa 2004, Martimort and Stole 2004, for examples). In these models, the transfers to the common
agent depends only on the amount each principal transacts with the agent. This assumption has two
justifications. The first one relates to the informational set-up. If the contractual clauses that organize
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product flows are either not observable by the agent’s clients or not verifiable in court, then each
principal’s transfer payments should depend exclusively on its own quantity. The second justification
has its roots in the institutional context. Indeed, product market transactions are subject to no-
discrimination rules which are enforced by antitrust authorities.
Our paper builds on other well-established specifications of a distinct literature on the industrial
organization of R&D as discussed in the introduction (d’Aspremont and Jacquemin 1988, Kamien,
Muller and Zang 1992a, Amir 2000). That literature assumes that information is complete and that
observable R&D efforts are verifiable. Consequently, firms may (horizontally) contract on their respec-
tive choice variables when they choose to cooperate in the R&D stage. Moreover, all papers which
compare R&D cooperation versus non-cooperation are based on the fact that antitrust rules on R&D
are less stringent than those on product markets.14
Many cooperative agreements typically involve rivals that collaborate horizontally at the pre-
competitive stage by coordinating the use of proprietary R&D facilities. These types of agreements
are well analyzed by the means of existing models of R&D cooperation. However, the stylised facts
that are descriptive of some other agreements are better captured by the specifications of our delegated
R&D model. For example, Katz et al. (1990, pp. 186-190) describe the case of MCC (Microelectronics
and Computer Technology Corporation), which became “an open-market supplier of contract R&D” to
supply application-oriented “deliverables” to large firms (e.g., Hewlett-Packard, Motorola, Honeywell,
Westinghouse Electric). More recently, Majewski (2004), who uses detailed contract-level data on R&D
projects that filed for protection under the US National Cooperation Research Act, documents many
cases where horizontal competitors in product markets actually outsource their R&D project to an
independent for-profit R&D entity.15
In addition, many R&D contracts have complex contractual clauses that authorize a fine tuning
between the payments of a given firm and the R&D services the laboratory may supply to other firms
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(see http://contracts.onecle.com for a large sample of contracts). For example, in the late 1990s Tularik
– a Californian independent laboratory that specializes in the research and development of therapeutic
pharmaceutical products based on a proprietary technology – signed a series of bilateral multi-annual
contracts for the delivery of firm-specific and nevertheless technologically related R&D services to a set
of American, Japanese, and European firms. The latter include Merck, Sumitomo Pharmaceuticals,
and Roche Bioscience, which can be rivals on final markets for pharmaceutical products. In these
contracts, one reads clauses that explicitly acknowledge the existing contractual links which involve
the common laboratory, with a nominative list of third parties. Some other clauses also stipulate that
the laboratory may not transfer any R&D output resulting from the contractual agreement without
the prior written consent of the particular firm that originated it. In some cases, the firm has an option
to purchase the rights to some identified R&D outcomes of the laboratory, before such opportunity is
offered to any third party (the so-called “right of first refusal”), for a certain period of time from the
date of the result. That period, together with the technological breadth of the rights, and the financial
terms, are all negotiable. This actually forms a link between a given firm’s transfer payments and the
R&D outputs received by all other laboratory’s clients.
In view of our objective to compare the performance of the delegated R&D game with standard
cooperative and non-cooperative models, we substitute the specifications of the literature of reference on
R&D for the assumptions that apply in the case of contractual arrangements between wholesalers and a
common retailer. The assumed verifiability of choice variables, the specificity of antitrust rules toward
R&D agreements, and the observed clauses in sample contracts, justify the assumption that firms
condition their payments to an independent laboratory on the level of R&D services their competitors
may receive.16
Several explanations for the fact that buyers of new knowledge write contracts exist in the liter-
ature. In a cross-sectorial empirical analysis, Veugelers (1997) remarks that when in-house facilities
are available, as we assume here, the capacity to go for it alone increases a firm’s bargaining power in
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negotiating with an external laboratory. On the intermediate market for biotechnology, where R&D
buyers are large pharmaceutical, agribusiness, or chemical firms, Lerner and Merges (1998) evoke the
financial constraints faced by specialized laboratories, and Argyres and Liebeskind (2002) refer to a
high rate of entry on the supply side. In the words of Hagedoorn and Roijakkers (2006), we focus
on cases in which “one partner, typically a large firm, contracts another, usually a small, partner to
develop a specific technology” (p. 434).
The timing of the delegated R&D common agency game is as follows. In a first stage, the two
firms (principals) simultaneously and non-cooperatively offers contingent transfer payments ti(x) to
the independent laboratory (an agent). In a second stage, given t ≡ (t1, t2), the laboratory accepts
either both contracts, or only one, or none. Then it chooses the verifiable amounts of firm-specific
R&D services, at a cost s(x), to maximize its own benefits given by:
L(x) = t1(x) + t2(x)− s(x). (10)
The third stage is as the final stage in the other two games.
Note that if the laboratory refuses all contracts it produces no R&D services and earns zero benefits.
This outside option leads to the following participation constraint:
L ≥ 0. (11)
When discussing policy implications later, we shall consider situations where (11) holds with strict
inequality. This would be the case if the laboratory incurs positive (arbitrarily small) installation
costs, or faces a profitable outside option. Finally, we denote the set of R&D services which, given
strategies t, maximize the laboratory’s benefits by:




In this model, identical firms address symmetric contingent transfer proposals to the laboratory.
This does not imply that equilibrium R&D services, and the related equilibrium payments, are sym-
metric across firms. While in the cooperative R&D game the ex-ante equal treatment of firms (in
the sense of Leahy and Neary (2005)) applies when side-payments between firms are ruled out, in the
delegated R&D game there is no reason to constrain a priori the laboratory to supply symmetric R&D
output. In fact, Section 3 establishes that for some parameter values the laboratory may serve only
one firm in equilibrium.
To compare the delegation of R&D with the cooperative and non-cooperative reference cases, we
maintain the assumption that information is complete among firms. However, this does not extend
to the laboratory which needs not know downstream cost and demand functions. An outcome of the
delegated R&D game is a three-tuple (xd, td,qd), where xd denotes the laboratory’s equilibrium choice,
td firms’ equilibrium payments, and qd equilibrium quantities on the final market. In this game firm
i’s net profit, as a function of x, equals:
pidi (x) ≡ pii(q
∗(x),x)− tdi (x). (13)
The laboratory bears all R&D costs, while the functional form of firms’ net profits in the delegated
R&D game is similar to Cre´mer and Riordan (1987) who model multilateral transactions with bilateral
contracts, but with transfer payments that are here contingent on the laboratory’s choice of R&D
outputs.17 For this game, by equilibria we mean truthful subgame-perfect Nash equilibria, which are
defined as follows.
Definition 3 (TSPNE) The equilibrium delegated R&D outcomes, transfer payments, and equilib-
rium quantities (xd, td,qd) are a truthful subgame-perfect Nash equilibrium if:
i) qd ≡ q∗(xd), where q∗(x) is a NE as in Definition 1;
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ii) (xd, td) is a NE, that is xd ∈ X(td) and there is no i = 1, 2, ti ∈ T , and no x ∈ X(ti, t
d
j ) such




iii) tdi is truthful relative to x
d, that is for all x either pidi (x) = pi
d
i (x




tdi (x) = 0, i, j = 1, 2, i 6= j.
Substituting xd into (13) gives a firm’s net equilibrium profits which, when symmetric, are denoted by
pid.
Intuitively, in any truthful equilibrium, a firm offers a transfer tdi (x) that reflects exactly its indi-
vidual valuation of the laboratory’s choice of x with respect to xd, all x. Definition 3-iii) refers to two
possible cases. Either gross profits pii(q
∗(x),x) exceed net equilibrium profits pii(q
d,xd)− tdi (x
d), and
the difference between transfer offers tdi (x
d) and tdi (x) is set equal to the difference between gross profits
pii(q
d,xd) and pii(q
∗(x),x). Or principal i’s gross profits with x are strictly less than net equilibrium
profits obtained with xd, in which case the transfer tdi (x) is set to zero.
As formally stated in Definition 3, the truthful equilibrium concept refers to a menu of payments
which, when non zero, are equal to the difference between each principal’s gross payoff for any possible
output of the agent and a constant. In this game, the constant is the net equilibrium profit. Only
payments for the output that is actually supplied are received by the agent in equilibrium. Bernheim
and Whinston (1986b), who first introduced the truthfulness refinement, also derive several properties
to characterize truthful equilibria in a class of delegated common agency games that includes our set-up.
A first property, when expressed in the terms of the present context, says that for any set of transfer
offers by any one of the two firms, there exists a truthful strategy in the other firm’s best-response
correspondence. This implies that a firm can restrict itself to truthful strategies. A second property
is that all truthful Nash equilibria are coalition-proof. In our case, this means that joint net profits,
as obtained in a truthful subgame-perfect equilibrium by the two firms, are higher than in any other
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subgame-perfect Nash equilibria.18 These two properties hold for all given choices of q in the final
stage, including q∗.
We acknowledge that non-truthful strategies may also be obtained as a Nash equilibrium in del-
egated common agency games. This property is made clear by Kirchsteiger and Prat (2001) who
introduce the definition of very simple strategies, which they call “natural”. A given principal’s trans-
fer payment is natural when it is strictly positive on only one agent’s output, and zero otherwise. This
describes an example of a forcing contract. Interestingly, while the first property (existence of truth-
ful strategies in a principal’s best-response correspondence) still applies to Nash equilibria in natural
strategies, the second property (coalition-proof) does not. Moreover, when there are only two princi-
pals, as in our model, a coalition-proof equilibrium is Pareto-efficient among principals.19 This offers
a strong justification for choosing truthful (subgame-perfect Nash) equilibrium as a solution concept.
3 Profits Maximization and Distribution
In this section, we examine how the laboratory’s choice compares with joint profits maximization, and
establish that the two firms purchase R&D services in equilibrium. We then derive a condition under
which the laboratory earns positive benefits. This condition partitions the (β, γ) space, which we refer
to as the externalities plane in the remainder of the paper.
We start be defining two externalities which will be helpful in discussing the results. Concentrated
profits pii(x) vary with the level of technological spillovers as measured by β. These spillovers are a
direct externality because firm i’s gross profits not only depend on xi, but also on xj for all β > 0.
These externalities are negative (positive) if an increase in xj has a negative (positive) impact on firm
i’s concentrated profits.
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In what follows, we identify positive (negative) direct externalities with β > (<)θ/2.
Within-laboratory technological conditions give rise to indirect externalities which appear only in
the delegated R&D game. We shall say that indirect externalities are negative (positive) if serving
higher quantities to a firm makes it more (less) costly for the laboratory to serve the other one, i.e.
if the production of R&D services are substitutable (complementary). More formally, for the cost
function (8):











Typically, R&D services are complements (i.e., δ > 0) when the laboratory can serve the two firms
by using the same resources. They are substitutes (i.e., δ < 0) when there are bottlenecks in the
laboratory’s capacity to simultaneously supply the two firm-specific services.





Proposition 1 (Joint Profits Maximization and Common Laboratory) In all TSPNE in which
L ≥ 0,
i) The laboratory’s choice of R&D services to maximize its benefits (10) is equivalent to maximizing
aggregate benefits (14), and
ii) There exists a continuous strictly decreasing frontier in the externalities plane (β, δ), denoted by
δ¯, which takes values in the interval [−γ, γ) and lies below (θ/2, 0), such that:
(a) if δ ≤ δ¯ the laboratory serves one firm only;
(b) if δ > δ¯ the laboratory serves the two firms.
Proposition 1 contains two related claims. Claim i) is a restatement of Bernheim and Whinston
(1986b) adapted to our context. It states that the non-cooperative attempt by firms to maximize
individual profits, by delegating R&D, leads the laboratory to deliver a pair of R&D services which
maximizes the aggregate benefits of all parties, that is the two firms and the laboratory. This “ef-
ficiency” (from the viewpoint of firms and the laboratory only) result is rooted in the truthfulness
refinement concept, as discussed above. It specifies that the laboratory is offered two transfer sched-
ules which exactly reflect the respective shape of each firm’s gross profit function (that is, pii(q
d(x),x),
all x, i = 1, 2). The laboratory thus internalizes both direct and indirect externalities, and in equilib-
rium maximizes the sum of the two firms’ profits, net of R&D costs. This result is silent on consumers’
welfare. We will be able to address this issue once we compute the quantities of R&D services produced
by the laboratory and compare them to the two other games. This is the subject of section 4.1.
Claim ii) of Proposition 1 establishes that, depending on the level of δ, in equilibrium the laboratory
delivers R&D services either to one firm only (either firm 1 or firm 2, indifferently), or to both of them.
The latter situation occurs when technological conditions do not penalize the production of a two-
dimensional R&D output, and transfer payments incentivize the laboratory to serve the two firms. In
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this case, there exists an interior solution to the joint-profit maximization problem, where (14) is the
maximand.
For a specific example, let a = 1, b = 1, c = 3/4, γ = 2, and θ = 1. Then consider two points in
[0, 1] × [−2, 2) above the frontier δ¯ = 2 (1− β)2 − 2 (see Figure 1), say (1/5,−1/5) and (4/5,−1/5).
The latter point lies in the South-East quadrant of the externalities plane, above the frontier δL=0,
implying that firms absorb all R&D benefits. Each of them receives xd ≈ 0.068 in exchange of a
payment td ≈ 0.050 and earns pid ≈ 0.010, while L = 0. By contrast, the former point is located below
δL=0 in the South-West quadrant, therefore the laboratory earns positive benefits. At that point, each
firm receives xd ≈ 0.035, pays td ≈ 0.004, and earns pid ≈ 0.005. The laboratory earns L ≈ 0.005.20




compare the equilibrium outcomes of the delegated R&D game with the ones obtained in the benchmark
cooperative and non-cooperative R&D games.
When δ is close to the lower bound −γ, a problem of congestion arises, in which case firms’ payment
schemes incentivize the laboratory to specialize in the production of only one line of R&D services. Since
the frontier δ¯ decreases when β increases, the congestion is more frequent when direct externalities are
low. Then the joint-profit maximization problem calls for a corner solution.21 In the latter situation,
recall that the asymmetry in the supplied R&D levels is captured by firms’ respective transfer payments
to the laboratory. From the truthfulness property, we know that each firm’s offered payments exactly
reflect its individual valuation of x. This implies that, in equilibrium, the two identical firms earn the
same net positive profits, we denote by p¯id, although R&D levels are asymmetric, for x¯d1 = 0 < x¯
d
2 (when









− p¯id. It is straightforward to check that 0 ≤ t¯d1 < (=)t¯
d
2 for all
β < (=)1. Whenever t¯d1 is positive, firm 1 participates in the financing of the R&D output, although
21
it does not receive anything directly from the laboratory. It benefits from firm 2’s purchased R&D
through spillovers.
Denote by Λ the maximum aggregate benefits obtained by maximizing (14) with respect to x. The
following proposition partitions the externalities plane.
Proposition 2 (Joint Profits Distribution) There exists a continuous strictly decreasing frontier
in the externalities plane (β, δ), denoted by δL=0, and which includes the point (θ/2, 0), such that in all
TSPNE the laboratory earns positive benefits if δ < δL=0, and exactly breaks even otherwise.
Proposition 2 says that the magnitude of indirect externalities (δ), for a given value of direct exter-
nalities (β), determines the laboratory’s ability to appropriate a share of innovation benefits, and thus
laboratory’s participation constraint (11) to be slack or binding. This is because indirect externalities,
in combination with inter-firm technological spillovers, impact the nature of competition between the
two firms on the intermediate market for R&D. This competition is reflected by their offers of transfer
payments (td1(x), t
d
2(x)). On the one hand, if both externalities are negative, a firm’s concentrated prof-
its decrease with the other firm’s R&D (Property 1), and serving one firm increases the laboratory’s
cost of serving the other (Property 2). This is a case of tough competition between the two firms for the
laboratory’s services, which is a source of positive profits for it. On the other hand, if both externalities
are positive, a firm’s concentrated profits are increasing in the other firm’s R&D, and serving one firm
decreases the laboratory’s cost of serving the other. Thus, competition for the laboratory’s resources
is relatively soft and the laboratory earns no benefits. When the externalities are of opposite signs, the
laboratory’s ability to appropriate benefits depends on their magnitudes. This opposition gives rise to
δL=0, which can thus be viewed as a weighted sum of direct and indirect externalities.
Propositions 1 and 2 are useful for the comparison of the outcomes of the three R&D games at the
pivotal no-externalities point (β, δ) = (θ/2, 0).
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Proposition 3 (The No-Externalities Case) The outcomes of the three games are the same at the
pivotal no-externalities point.
At the pivotal point, there are no direct and indirect externalities. This implies that solutions in
x are the same in the three R&D games. In the delegated game the laboratory earns zero benefits,
as if firms were relying on in-house R&D capabilities, because (β, δ) = (θ/2, 0) is on δL=0. We now
solve the three R&D games by backward induction and rank the performance of the three games in
the externalities plane. The explicit solutions of the games are in Appendix A.
4 Comparing the Three Games
We partition the externalities plane by deriving frontiers on which R&D, profits, or welfare are equal
in the delegated R&D game and in one of the two alternative games. By welfare, we mean the sum of
consumer surplus, firms’ profits, and the laboratory’s benefits. For the sake of completeness, we also
include the comparison of the outcomes of the cooperative and non-comparative games as established
by d’Aspremont and Jacquemin (1988). In the delegated R&D game, we focus on interior solutions
to the joint-profit maximization problem, as solved by the laboratory by reacting to payment offers
to maximize its own benefits. Note from the onset that, as a result of Proposition 3 all such frontiers
include the pivotal no-externalities point.
4.1 R&D outcomes
Lemma 1 (Cooperative, Non-Cooperative, and Delegated R&D)
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i) There exists a continuous frontier δxd=xc in the externalities plane such that in all TSPNE
xd >=
<
xc if and only if δ >=
<
δxd=xc, with
δL=0 > δxd=xc = 0 for β < θ/2;
δL=0 = δxd=xc = 0 for β = θ/2;
δL=0 < δxd=xc = 0 for β > θ/2.
ii) There exists a continuous frontier δxd=xn in the externalities plane, such that in all TSPNE
xd >=
<
xn if and only if δ >=
<
δxd=xn, with
0 < δxd=xn < δL=0 for β < θ/2;
δL=0 = δxd=xn = 0 for β = θ/2;
0 > δxd=xn > δL=0 for β > θ/2.
Direct and indirect externalities combine to give Lemma 1. First consider Lemma 1-(i). The
cooperative and delegated games yield the same R&D solution when there are no indirect externalities
because of Proposition 1 (which says that the laboratory maximizes aggregate benefits in equilibrium),
and of Property 2 (which implies that costs are the same in both games when δ = 0). We know that the
independent laboratory is more (less) efficient than in-house laboratories when indirect externalities
are positive (negative), that is when δ > 0 (δ < 0). This completes the partitioning of the externalities
plane for R&D output in the two games under scrutiny.
Second, consider Lemma 1-(ii). Recall that, from Property 1, optimal R&D is greater (smaller) in
the cooperative than in the non-cooperative game for positive (negative) direct externalities. Let direct
externalities be positive. If indirect externalities are also positive, the laboratory’s higher efficiency
means that delegated R&D exceeds the cooperative, and hence the non-cooperative, solutions. If
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indirect externalities are negative, the laboratory is at a disadvantage in the production of R&D
over in-house laboratories. However, as it internalizes inter-firm direct externalities via the transfer
payments it receives, it is only for sufficiently negative indirect externalities that non-cooperative R&D
exceeds the delegated game solution. Consequently, δxd=xn must cross in the South-East quadrant of
the externalities plane.
Now let direct externalities be negative. If indirect externalities are also negative, the laboratory’s
lower efficiency than in-house laboratories means that the delegated solution is smaller than the coop-
erative and (by transitivity) the non-cooperative one. However, as the laboratory gains in efficiency
as δ increases, there exist sufficiently high positive indirect externalities for the R&D outcome under
the delegated game to exceed that under the non-cooperative game. Hence δxd=xn must lie in the
North-West quadrant of the externalities plane.
[Insert figure 1 about here]
The juxtaposition of δxd=xc and δxd=xn in the externalities plane, as illustrated in Figure 1, allows us
to rank optimal R&D across the three games. It is of interest that optimal R&D in the delegated game
is greater than in either of the two games for sufficiently high indirect externalities, even when direct
externalities are negative. This result stands in contrast with cooperative R&D always being less than
non-cooperative one for negative direct externalities.
4.2 Firms’ Profits
Lemma 2 (Cooperative, Non-Cooperative, and Delegated Profits)
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i) There exists a continuous frontier δpid=pic in the externalities plane such that in all TSPNE
pid >=
<
pic if and only if δ >=
<
δpid=pic, with
0 < δpid=pic < δL=0 for β < θ/2;
δpid=pic = δL=0 = 0 for β = θ/2;
0 = δpid=pic > δL=0 for β > θ/2.
ii) There exists a continuous frontier δpid=pin in the externalities plane such that in all TSPNE
pid >=
<
pin if and only if δ >=
<
δpid=pin, with
0 < δxd=xn < δpid=pin < δpid=pic for β < θ/2;
δxd=xn = δpid=pin = δpid=pic = 0 for β = θ/2;
0 = δpid=pic > δpid=pin > δxd=xn for β > θ/2.
The intuition for δpid=pic follows also from how the two externalities combine. For the same reasons
as in Section 4.1, aggregate benefits are ceteris paribus increasing in indirect externalities. However,
when part of the aggregate benefits accrue to the laboratory, which is the case for δ < δL=0, then
indirect externalities must be sufficiently positive to generate enough surplus to compensate for the
laboratory’s benefits. Hence, if direct externalities are negative, the locus which equalizes firms’ profits
in the delegated and cooperative games must lie in the North-West quadrant of the externalities plane.
It cannot however lie above δL=0 where aggregate benefits in the delegated game exceed those in the
cooperative game, but are divided equally between the two firms. If direct externalities are positive,
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the frontier is confounded with δ = 0 because of Proposition 1, the cost structure being the same in
both games and the laboratory earning zero benefits.
The intuition for the δpid=pin locus is as follows. Recall that a firm’s profits in the cooperative game
always exceed those under the non-cooperative one because cooperation internalizes direct externalities
and prevents R&D duplication. As a firm’s profits in both the cooperative and delegated games are
equal along δpid=pic , by transitivity delegated profits exceed non-cooperative ones along that locus.
Consider negative direct externalities. For δ = 0, along that line cooperative profits are greater than
those obtained in the delegated game. However, firms’ profits in the delegated game are increasing in
indirect externalities (Lemma D-2 in Appendix D). Hence, there exists a unique decreasing continuous
locus in the North-West quadrant of Figure 2 such that pid = pin.
By the same token, there must exist a locus in the South-East quadrant of Figure 2 which equalizes
profits in the delegated and non-cooperative games. That locus must lie below δxd=xn for the following
reason. Along δxd=xn optimal R&D expenditures are equal in both the delegated and non-cooperative
games. However, the laboratory is less efficient than in-house R&D when there are negative indirect
externalities. It follows that aggregate benefits in the non-cooperative game exceed those in the dele-
gated game along that locus. As the laboratory does not earn negative profits, pid < pin along δxd=xn .
Therefore δpid=pin lies above δxd=xn .
[Insert figure 2 about here]
Figure 2 graphs δpid=pic and δpid=pin to compare firms’ profits in the three games. As expected, firms’
profits are highest in the delegated game when both externalities are positive. However, delegated R&D
may yield the lowest profits even if direct externalities are weakly negative and indirect externalities are
weakly positive (region below δpid=pin in Figure 2). This occurs because in that region the laboratory
earns positive benefits and indirect externalities do not have a high enough impact on aggregate benefits.
Hence, positive indirect externalities are necessary but not sufficient for firms to prefer the delegated
27
game to the other two. Note that the firms’ profits results have a benchmark flavor, in the sense
that the net benefits obtained by a laboratory endowed with some informational advantage, would be
bounded from below by the equilibrium benefits obtained here.
4.3 Welfare
Lemma 3 (Cooperative, Non-Cooperative, and Delegated Welfare)
i) There exists a continuous frontier δwd=wc in the externalities plane such that in all TSPNE
wd >=
<
wc if and only if δ >=
<
δwd=wc, with
0 = δwd=wc < δL=0 for β < θ/2;
0 = δwd=wc = δL=0 for β = θ/2;
0 = δwd=wc > δL=0 for β > θ/2.
ii) There exists a continuous frontier δwd=wn in the externalities plane such that in all TSPNE
wd >=
<
wn if and only if δ >=
<
δwd=wn, with
0 < δwd=wn < δxd=xn < δpid=pin for β < θ/2;
δwd=wn = δxd=xn = δpid=pin = 0 for β = θ/2;
0 > δpid=pin > δwd=wn > δxd=xn for β > θ/2.
The frontier δwd=wc is the direct consequence of Property 2, Proposition 1, and aggregate benefits
being increasing in indirect externalities. To understand the intuition for δwd=wn , let direct externalities
be negative (i.e., β < θ/2). If δ = 0 in that region, both optimal R&D and firms’ profits in the
delegated game are smaller than in the non-cooperative game by Lemmas 1-(ii) and 2-(ii) respectively.
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Therefore, when indirect externalities are negative, wd < wn along δ = 0. Second, aggregate benefits
in the delegated game must be greater than in the non-cooperative game along δxd=xn because the
laboratory is more efficient than in-house R&D facilities, and by definition the same amount of R&D is
performed in both games. Moreover, wd is increasing in δ (see Lemma D-3 in Appendix D). It follows
that for each β in the region bounded by δ = 0 and δxd=xn , there exists a value for δ such that welfare
in the delegated and non-cooperative games are equal. The existence of δwd=wn in the South-East
quadrant of the externalities plane can be rationalized in the same way.
[Insert figure 3 about here]
It is worth noting that our analysis, and all the results, can be extended to a variant of the
cooperative game. In this amended set-up, firms could still run their two independent laboratories
but benefit from complementarities in the production of R&D outputs. In this case, the cost of doing
R&D would be the same as in the delegated R&D game with a non-negative δ. Recall now from
Proposition 1 that the laboratory acts as a ”social planner” by choosing the quantities of R&D which
maximize aggregate benefits, i.e. its own benefits and the sum of the two firms’ profits. This implies
that the objective function where both firms cooperate and there are complementarities across their
R&D activities is identical to the objective function of the R&D delegated game.
It follows that, in this alternative cooperative R&D model, the optimal R&D level accruing to
each firm, as well as the welfare level, would be identical to the ones of the delegated R&D game in
equilibrium. Only firms’ profits across the two games may differ for some parameter values. To see that,
recall from Proposition 2 that the externalities plane (β, δ) can be partitioned into two subspaces: one
where the laboratory earns no benefits, and another one where the laboratory earns positive benefits.
In the alternative cooperative R&D game, any positive profits the laboratory earns in the delegated
game would be equally divided between the two firms.
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One could thus derive new frontiers in the externalities plane, on which firms’ symmetric profits
p¯ic in the alternative cooperative R&D game are equal to those obtained in any of the other games.
Section E in the Appendix proves that the profit frontiers for the comparison of pic with pic and pin
coincide with the ones we derived in Lemma 2 for the comparison of pid with pic and pin, whenever
the laboratory earns no benefits, that is above the frontier δL=0 in Figure 2. This is because, in the
latter subspace, firms earn the same equilibrium profits in the alternative cooperative R&D game as
in the delegated R&D game. By contrast, strictly below δL=0, each firm earns higher equilibrium
profits in the alternative cooperative R&D game than in the delegated R&D game where the common
independent laboratory appropriates some benefits. One finds also that p¯ic = pic if and only if δ = 0,
and that p¯ic > pin for all δ ≥ 0. The intuition for this result is that, when complementarities are present,
cooperative firms in the alternative model cannot be worse-off than in the benchmark cooperative R&D
game where no cost complementarities are specified, and a fortiori in the non-cooperative R&D set-up.
From firms’ viewpoint, this new cooperative game thus leads to the best of possible worlds. How-
ever, comparing this new model with the two benchmark ones and with our delegated R&D model is
somewhat artificial. Indeed, the introduction of complementarities across firms as manna from heaven,
on top of cooperation stricto sensu, is equivalent to assuming that firms jointly acquired the external
laboratory without paying anything. Thus, the fact that firms would prefer the new cooperative game
to anything else should not come as a surprise. In addition, the existence of cost complementarities in
the production of R&D is more realistic in a R&D joint-venture – in which firms may also choose the
level of spillovers – than in a simple R&D cartel. In a R&D joint-venture, firms will find it profitable
to choose β = 1 (see Amir et al. (2003)), in which case equilibrium profits in the new model and in the
delegated one are identical, as for any β ≥ θ/2. In what follows we keep focusing on the main three
models introduced in Section 2.
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5 Pareto Optimal R&D Organization and Policy Discussion
The juxtaposition of Proposition 2, Lemmas 1, 2 and 3 in the externalities plane allows us to investigate
whether one of the three games can Pareto-dominate the other two.
Theorem 1 The frontiers established in Proposition 2 and Lemmas 1, 2 and 3 are such that:
δL=0 > δpid=pic > δpid=pin > δxd=xn > δwd=wn > δwd=wc = δxd=xc = 0 for 0 ≤ β < θ/2;
δL=0 = δpid=pic = δpid=pin = δxd=xn = δwd=wn = δwd=wc = δxd=xc = 0 for β = θ/2;
0 = δxd=xc = δpid=pic = δwd=wc > δpid=pin > δwd=wn > δxd=xn > δL=0 for θ/2 < β ≤ 1.
(15)
All frontiers are defined on [−γ, γ), and the fact they intersect for β = θ/2 stems from Proposition
3. For (β, δ) such that 0 ≤ β < θ/2 and δL=0 < δ < δpid=pic , the laboratory earns positive benefits
(as opposed to zero profits otherwise). Moreover, in that region, consumer surplus (as inferred from
R&D outcomes), and firms’ equilibrium profits, are strictly higher in the delegated game than in the
equilibria of cooperative and non-cooperative games. This does not hold elsewhere in the externalities
plane, as can be checked from (15).
Corollary 1 (Delegation Dominance) The delegated R&D game Pareto dominates the other two
games, and the laboratory earns positive profits, for 0 ≤ β < θ/2 and δpid=pic < δ < δL=0.
We have therefore established that for certain levels of externalities, consumers, firms, and the
laboratory all benefit from the delegation of R&D. Therefore, delegated R&D is a Pareto optimal
organizational form. For simple reasons, this cannot occur when direct and indirect externalities are
positive. In that case, the delegated game yields the highest profits and consumer surplus, but the
laboratory earns no benefits because firms’ interests are congruent. For opposite reasons, welfare is
minimized under the delegated game if both direct and indirect externalities are sufficiently negative,
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although in this case a laboratory would earn positive profits. What is crucial for the delegated R&D
game to Pareto dominate the other two games, is that indirect externalities must not be too high, so
that the firms must still compete for the laboratory’s resources, which thus earns positive benefits and
participates. But indirect externalities must be high enough to make welfare greater than in the other
two games, and let firms obtain more of it than under the two other options.
[Insert figure 4 about here]
We can now use these results to examine when the interests of firms and consumers conflict or
coincide. This is an important question because firms decide to delegate R&D only if it is profitable for
them to do so, and if the laboratory participates. We find that, although no one asks for consumers’
consent, firms’ privately profitable decision to delegate R&D is always socially optimal. To see that,
remark first that in all three games consumer surplus increases with R&D because lower costs lead
to higher quantities and lower prices (see Appendix D-3). Second, in the externalities plane, for all
values of direct spillovers, firms find it more profitable to delegate R&D than to do R&D in-house
either cooperatively or non-cooperatively if and only if δ is above δpid=pic (Theorem 1). Now observe
that δpid=pic is the “highest” profit frontier and that it is also always above the two frontiers δxd=xc and
δxd=xn which allow us to compare the consumer surpluses obtained in all three games equilibria (see
Figures 1 and 2). Hence, firms never find it profitable to delegate R&D with consumers being worse
off than in either of the two other games (as would be the case if we had, say, δpid=pic < δxd=xc for some
values of β).
A more striking result is obtained when the laboratory must earn strictly positive profits to par-
ticipate (i.e., (11) is replaced by L > 0). This occurs if the laboratory has an outside option where
it can earn some arbitrarily small positive net benefits. In that case, firms delegate R&D only if δ is
between δpid=pic and δL=0 when direct externalities are negative (i.e., 0 ≤ β < θ/2). They cannot rely
on the laboratory’s R&D services when direct externalities are positive (i.e. θ/2 < β ≤ 1) because the
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frontier above which the laboratory earns zero benefits (δL=0) lies below all the other frontiers in that
region (see Figure 2). Consequently, when the laboratory must make positive benefits to participate,
firms will profitably delegate R&D services only when externalities fall in the Pareto dominating region
defined in Corollary 1 and which corresponds to the shaded area in Figure 4. A straightforward policy
implication is that, when firms behave as described here, there is no motivation for a regulator to
constrain firms’ choice to delegate R&D.
6 Conclusion
R&D outsourcing (delegation) is an increasingly important phenomenon, and many rivals delegate
R&D to a common independent laboratory. While many theoretical industrial organization models
compare the outcomes of firms doing R&D cooperatively or non-cooperatively, none has, to the best
of our knowledge, investigated R&D delegation in a formal set-up and compared the three modes of
R&D. This paper fills that gap by setting up a simple model where competitors can independently
choose to delegate R&D to a profit-maximizing laboratory.
Our model of delegated R&D builds on the literature where a firm’s R&D reduces not only its unit
cost of production but also that of its competitor through technological spillovers (direct externalities).
The R&D projects which firms delegate to the laboratory give rise to an additional externality because
they can be complements (positive indirect externalities), substitutes (negative indirect externalities),
or independent. Positive (negative) indirect externalities can be associated with economies of scope
(a congestion) in the production of R&D. We characterize the impact of these two externalities on
delegated R&D outcomes, firms’ profits, social welfare, and the laboratory’s benefits. We compare the
outcomes of delegated R&D to an independent profit-maximizing laboratory to firms doing in-house
R&D either non-cooperatively or cooperatively. One interesting aspect of our analysis is the ability to
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illustrate the results graphically by fully partitioning the plane of between-firm technological spillovers
and within-laboratory R&D externalities, for all dimensions of the comparison.
We establish a number of novel results. First, only one firm receives R&D services if direct and
indirect externalities are relatively low. Otherwise, assuming the laboratory participates whenever it
earns non-negative benefits, sufficiently high direct and indirect externalities are necessary and sufficient
for optimal R&D, firms’ profits, and social welfare to be highest in the delegated R&D game. Second,
assuming the common laboratory needs positive benefits to participate, positive indirect externalities
are not sufficient for firms to delegate R&D. Firms will opt for R&D delegation to a for-profit common
laboratory if indirect externalities are not too positive when direct externalities are negative. When
indirect externalities are too high they counteract direct externalities and the laboratory only breaks
even. Third, there always exists a region in the externalities plane where the laboratory earns positive
benefits and the delegated R&D game Pareto-dominates the other two games if (i) direct externalities
are sufficiently negative (for firms to compete for the laboratory’s services); and (ii) indirect externalities
are positive (so that firms benefit from economies of scope) but not too high (for the laboratory to earn
positive benefits). Finally, our findings have a laissez-faire flavor: no regulatory intervention is required
when firms decide to delegate R&D to a profit-seeking laboratory. This strong statement arises because,
in this model, firms privately profitable choice to contract with a laboratory also benefits consumers.
This paper is a first step in the analysis of procurement markets for new technology with multiple
buyers. Since we use standard yet specific algebraic specifications of the cost and demand functions,
future work could also test the robustness of the results to changes in the formal specifications of the
compared games. We proceed in that direction by using Amir (2000) to specify a modified cost function
for the laboratory so as to investigate situations where R&D is conceived as expenditures (i.e., inputs),
rather than outputs.22 All our results remain valid. In another positive test of robustness, we show
that our results are qualitatively similar when firms behave a` la Bertrand in the product market stage
of all three R&D games. These proofs are available from the authors upon request.
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Another interesting extension would be to examine the relationship between R&D outsourcing
and absorptive capacity. Instead of comparing R&D delegation with benchmark set-ups, as in the
present paper, it is possible to construct a model in which each firm may simultaneously choose a
level of internal R&D (as in the cooperative and non-cooperative R&D models) and tap technological
knowledge from an external laboratory (as in the delegated R&D model). By introducing a formal
representation of absorptive capacity adapted from Kamien and Zang (2000), one would specify that
a firm may not benefit from the laboratory’s output if it produces no R&D of its own.
Among the open questions it remains to investigate what happens when R&D efforts lead to product
innovations. This could be done by assuming that R&D increases quality by using a framework in the
spirit of Symeonidis (2003). It would be also natural to consider more than two firms. However, beyond
usual tractability difficulties in computing the equilibrium, this would imply a qualitative leap in the
characterization of the joint benefits function of the laboratory and any subset of firms.23 Finally,
our analysis, and the whole literature on which it is based, can be criticized by its assumption of
deterministic R&D. To address that critique one may examine situations where the true cost of a R&D
program is unknown before it starts.24
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Appendix
A Explicit Solutions of the Three R&D Games
As standard we proceed backwards. Section A.1 solves for each firm’s output on the final market,
which is common to three games. Then section A.2 starts by defining some variables which to simplify
the notation and solves for a firm’s symmetric R&D in the cooperative (section A.2.1), non-cooperative
(section A.2.2) and delegated games respectively (section A.2.3).
A.1 Final Market Stage
Each firm chooses output to maximize its gross profits (3). This yields two reaction functions, which
we use to solve for each firm’s subgame Cournot-Nash equilibrium output as a function of x:
qi(x) =
α(2− θ) + (2− θβ)xi − (θ − 2β)xj
(2− θ)(2 + θ)b
, (16)
for i, j = 1, 2, i 6= j, and where α ≡ a− c. Making use of (1) and (16) into (3) we obtain:
pii(x) = b[qi(x)]
2, (17)
for i = 1, 2. Now we turn to the R&D stage which is game-specific.
A.2 R&D Stage
Define the following two terms:
Γ1 ≡ bγ (2 + θ)
2 − 2 (1 + β)2 ,
Γ2 ≡ bγ (2− θ)
2 (2 + θ)2 − 2 (2− θβ)2 .
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In the remainder of the paper, we assume that Γ1 and Γ2 are positive. The assumption Γ1 > 0 is
a sufficient second-order condition for a symmetric optimum in the cooperative game when firms are
treated equally ex-ante (in the sense of Leahy and Neary, 2005). The assumption Γ2 > 0 ensures the
objective functions in the non-cooperative game are concave. Note, however, that in the latter game,
Henriques (1990) establishes that the reaction functions in the R&D space cross “correctly” when
|∂xi/∂xj | is less than 1. Using our notation this condition imposes a stronger restriction on Γ2:
Γ2 > |2 (2− βθ) (2β − θ)|. (18)
Remark that (18) holds for all values of β when b = θ = 1 and γ = 2, which are the values used to
draw Figures 1 to 4.
Finally, we define:
Γ3 ≡ bγ(2− θ)(2 + θ)
2 − 2(1 + β)(2− θβ),
which we also assume to be positive for economic sense in what follows. We will use Γ1, Γ2, and Γ3 to
simplify the notation.
A.2.1 Cooperative R&D







where pi1(x) and pi2(x) are given by (17). We maximize (19) with respect to x1 and x2 to obtain the
symmetric cooperative R&D outcome and the profits of each individual firm respectively as:
xc = 2 (1 + β)α/Γ1, (20)
pic = γα2/Γ1. (21)
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A.2.2 Non-Cooperative R&D
Each firm chooses its R&D independently to maximize its net profits (7). This yields two reaction
functions which we use to solve for a symmetric non-cooperative R&D outcome:
xn = 2α(2− θβ)/Γ3. (22)






Proposition 1 states that the choice of R&D services by the laboratory is equivalent to maximizing
aggregate benefits (14) with respect to x1 and x2. Assuming that the laboratory may treat firms
differently (see the ex-post equal treatment case in Leahy and Neary, 2005), second-order conditions
for a symmetric solution are:
b(γ − δ) (2 + θ)2 − 2 (1 + β)2 > 0 and b (γ + δ) (2− θ)2 − 2 (1− β)2 > 0. (24)
This can be rewritten as follows:
2 (1− β)2 − bγ (2− θ)2
b (2− θ)2
< δ <
bγ (2 + θ)2 − 2 (1 + β)2
b (2 + θ)2
. (25)
It is easy to check that the lower bound of the latter interval is greater than −γ, whereas the upper
bound is strictly less than γ. This says that a symmetric solution is obtained if δ does not take extreme
values inside [−γ, γ).
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− (γ − δ)xi = 0, (26)
i, j = 1, 2, i 6= j. This gives each firm’s symmetric delegated R&D outcome:
xd = 2 (1 + β)α/Γ4, (27)
where Γ4 ≡ b(γ− δ) (2 + θ)
2−2 (1 + β)2, which is unambiguously positive from (24). Substituting (27)
into (14), using the laboratory’s explicit cost function (8), and simplifying gives aggregate benefits:
Λ = 2 (γ − δ)α2/Γ4. (28)
B Proofs of Properties 1 and 2




2 (2β − θ)
(2− θ) (2 + θ)
qi(x), (29)
for i = 1, 2, i 6= j. As θ ∈ [0, 1], equation (29) is of the same sign as (2β − θ) for a positive output, or
equals zero otherwise.
The proof of Property 2 follows directly from differentiating (8) with respect to xi and xj .
C Proof of Propositions
C.1 Proof of Proposition 1
The proof of Proposition 1-(i) is a simple adaptation in the notation from Bernheim and Whinston
(1986b, first part of Theorem 2 on page 14, and proof on pages 24-25). It is available upon request
from the authors. We capitalize on this first result to prove Proposition 1-(ii). Since the choice of
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R&D services by the laboratory is equivalent to maximizing aggregate benefits (14) with respect to x1
and x2, we solve:
max
x≥0
Λ (x) . (30)
As a preliminary step, we first demonstrate that the stability condition (18) of the non-cooperative
R&D game implies that:
Γ2 − 2 (2β − θ)
2 > 0. (31)
To see this, remark that (18) imposes:
Γ2 + 2 (2− βθ) (2β − θ) > 0, (32)
and also:
Γ2 − 2 (2− βθ) (2β − θ) > 0. (33)
This leads to two cases: (i) if β < θ/2 then −2 (2β − θ)2 > 2 (2− βθ) (2β − θ), in which case
(32) ⇒ Γ2 − 2 (2β − θ)
2 > 0; (ii) if β ≥ θ/2 then −2 (2β − θ)2 ≥ −2 (2− βθ) (2β − θ), in which case
(33) ⇒ Γ2 − 2 (2β − θ)
2 > 0. It follows that, for the comparison of the delegated R&D game with the
non-cooperative R&D game to be meaningful, parameter values must be such that Γ2−2 (2β − θ)
2 > 0.
Next, we turn to the Kuhn-Tucker necessary conditions of (30), that is:
∂Λ (x)
∂xi




for i = 1, 2. We check that a candidate solution x¯, with x¯1 = 0 and x¯2 ≡ x¯
d > 0 (without loss of










= 0, leading to:
x¯d =
2α (1 + β) (2− θ)2
Γ2 − 2 (2β − θ)
2 , (35)
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≤ 0 if and only if:
2α (1 + β)
b
b (γ + δ) (2− θ)2 − 2 (1− β)2
Γ2 − 2 (2β − θ)
2 ≤ 0. (36)
Recalling that Γ2 − 2 (2β − θ)
2 > 0, we obtain that (36) is verified if and only if b (γ + δ) (2− θ)2 −
2 (1− β)2 ≤ 0. Then define the frontier:
δ¯ ≡
2 (1− β)2 − bγ (2− θ)2
b (2− θ)2
. (37)
This leads to two cases. Either:
























Γ2 − 2 (2β − θ)
2
(2− θ)2 (2 + θ)2
, (40)
which is always negative when the stability condition (18) of the non-cooperative game is satisfied
(since this implies Γ2 − 2 (2β − θ)
2 > 0, as shown above).
Eventually, to see that δ¯ exists in [−γ, γ), first consider the slope and curvature of δ¯ in the plane




















− γ, and δ¯
∣∣
β=1 = −γ. (42)
Eventually, Γ2− 2 (2β − θ)
2 > 0 for β = 0 implies γ > 8/b (2− θ)2 (2 + θ)2. As the latter threshold
is greater than 1/b (2− θ)2, by transitivity one obtains γ > 1/b (2− θ)2, leading to δ¯
∣∣
β=0 < γ.
C.2 Proof of Proposition 2
Let N = {1, 2}, and 2N = {∅, {1}, {2}, {1, 2}}. We build on Laussel and Le Breton (2001) – henceforth
LLB – by associating to the common agency game, as defined in section 2.3, a transferable utility






where s(x) is given by (8) and pii(x) by (17). This function gives the highest joint-benefits of the labo-
ratory and any subset S of firms in N , with Π(∅) = pi1(0, 0) + pi2(0, 0), that is the sum of concentrated
profits with no R&D (a normalization). Then the proof consists in investigating additive properties
of Π on 2N in order to exploit a series of theorems that characterize the equilibrium outcomes of the
delegated R&D game.
• From LLB’s Theorem 3.1 (p. 102), if Π(S) is strictly subadditive, that is:
Π({1, 2}) < Π({1}) + Π({2}), (44)
then the laboratory earns positive benefits in all equilibria, that is L > 0.
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• From LLB’s Theorem 3.3 (p. 104), if Π(S) is strictly subadditive, then #N = 2 implies that
firms’ symmetric profits in the delegated R&D game are:
Πd = Λ−Π({i}), (45)
i = 1, 2.
• From LLB’s Theorem 3.2 (p. 103), if Π(S) is superadditive, that is:
Π({1, 2}) ≥ Π({1}) + Π({2}), (46)
then L = 0. In that case, the fact that the laboratory maximizes aggregate benefits Λ(x) in (x)
(Proposition 1), together with the assumption that the symmetric firms are subject to “equal
treatment”, imply that a firm’s equilibrium profits in the delegated R&D game are:
pid = Λ/2. (47)
The remainder of the proof identifies values of δ which are such that Π(S) is either strictly subadditive
or superadditive. To that effect we solve for values of δ such that (46) holds with equality, to obtain
a frontier which we denote by δL=0. However, the free maximization of Π(S), for S = {i}, i = 1, 2,
may yield negative maximands. Therefore, we consider in turn the free-maximum and constrained-
maximum versions of (43), denoted by Πˇ({i}) and Πˆ({i}), respectively. We thus obtain two frontiers
δˇL=0 (free-maximum) and δˆL=0 (constrained-maximum) each of which verify (46) with equality. We
then calculate the values of δ for which the free maximand xˇj is equal to the constrained variable
xˆj ≡ 0, and denote it by δxˇj=xˆj=0. Finally, we compare δˆL=0 and δˇL=0 with δxˇj=xˆj=0 to verify for
which parameter values (i) δˇL=0 verifies the positive maximand constraint, and (ii) δˆL=0 verifies the
non-positive maximand constraint. This allows us to derive the frontier δL=0 by “pasting” those two
functions.
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C.2.1 Free and Constrained Solutions
















− 2 (2− θβ)2 .
We assume Γ5, Γ6, and Γ7 are positive for the following free-maximum problem to be concave:
Πˇ({i}) = max
x
(pii(x)− s(x)) , (48)
where s(x) is given by (8) and pii(x) by (17). Maximizing the right-hand side of (48) gives the following
unconstrained R&D solutions:
xˇi = 2α (2− θ) [δ (θ − 2β) + γ (θβ − 2)]/Γ5; (49)
xˇj = 2α (2− θ) [δ (θβ − 2) + γ (θ − 2β)]/Γ5. (50)
Making use of (49) and (50) into (48) we obtain, for i = 1, 2:





• Secondly, we solve the constrained-maximum versions of (43), with S = {i}, i = 1, 2. In this simpler
problem, the only concavity condition imposes that Γ7 > 0 to compute:
Πˆ({i}) = max
xi
(pii(xi, 0)− r(xi)) , (52)
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where r(xi) is given by (4), and pii(xi, 0) is obtained by setting xj = xˆj ≡ 0 in (17). Maximizing the
right-hand side of (52) gives the constrained R&D:
xˆi = 2 (a− c) (2− θβ) (2− θ)/Γ7. (53)
Substituting (53) into the right-hand side of (52) gives:
Πˆ({i}) = γα2(2− θ)2/Γ7, (54)
for i = 1, 2.









γ (2β − θ)
θβ − 2
≡ δxˇj=xˆj=0. (55)
C.2.2 The Laboratory’s Zero-Benefits Free-maximum Frontier
We evaluate (46), assuming it holds with equality with free-maximum profits to obtain:
Π({1, 2})− Πˇ({1})− Πˇ({2}) = 0, (56)
where Πˇ({1}) and Πˇ({2}) are given by (51). There are two roots to (56). The first is δ = γ, which
however violates (48). The second root is:
δ =
2γ (2− θβ) (θ − 2β)
(2− θβ)2 + (2β − θ)2
≡ δˇL=0. (57)
To check that (57) is compatible with free maximands, recall from (55) that (57) is defined only if
δˇL=0 ≥ δxˇj=xˆj=0. We form the difference:
δxˇj=xˆj=0 − δˇL=0, (58)
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and look for parameter values for which it is non-positive. Equating (58) to 0, we find that β = θ/2
and β = 1 are the only admissible roots (the other roots are γ = 0, θ = ±2, and β = −1.) Hence, (58)
changes sign at most once in the domain of β. Evaluating (58) at some parameter values, we find that
δˇL=0 is defined only for 0 ≤ β ≤ θ/2.
Finally, using (57), note that the frontier δˇL=0 includes (β, δ) = (θ/2, 0).
C.2.3 The Laboratory’s Zero-Benefits Constrained-maximum Frontier
As in C.2.2, we evaluate (46), assuming it holds with equality but using the constrained profits (54),








To check that the latter expression is compatible with a constrained maximand, recall from (55) that
(59) is defined only if δˆL=0 ≤ δxˇj=xˆj=0. Then form the difference:
δxˇj=xˆj=0 − δˆL=0, (60)
and look for the parameter values for which it is non-negative.
Equating (60) to 0 gives β = θ/2 as the only admissible root, and three non-admissible roots (γ = 0,
θ = 2, and β = −1). Hence, (60) changes sign once over the domain of β. Evaluating (59) at some
parameter values leads to the conclusion that (60) is defined only for θ/2 ≤ β ≤ 1.
Finally, using (59), note that, as for δˇL=0, the frontier δˆL=0 includes (β, δ) = (θ/2, 0).
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C.2.4 The Laboratory’s Zero-Benefits Frontier
By taking the conclusions of sections C.2.2 and C.2.3 together, we obtain that (46) holds with equality
if and only if:
δ = δL=0 =


δˇL=0 for 0 ≤ β ≤ θ/2,
δˆL=0 for θ/2 ≤ β ≤ 1,
(61)
where δˇL=0 and δˆL=0 are explicitly given by (57) and (59). Note that β = θ/2 implies δL=0 = δˇL=0 =
δˆL=0 = 0. We now prove that δL=0 is decreasing in β, by considering δˇL=0 and δˆL=0 in turn.
(δˇL=0) Differentiating (57) with respect to β and equating to 0 yields 5 roots (γ = 0, θ = ±2, or β = ±1),
none of which is admissible. It follows that δˇL=0 is strictly monotone over the domain of β on
which δˇL=0 is defined, that is [0, θ/2]. To complete the proof, let for instance β = θ/2, and check
that dδˇL=0/dβ < 0, as required.
(δˆL=0) Differentiating (59) with respect to β and equating to 0 yields 4 roots (γ = 0, θ = ±2, or β = −1),
none of which is admissible. It follows that δˆL=0 is strictly monotone over the domain of β on
which δˆL=0 is defined, that is [θ/2, 1]. To complete the proof, let, for instance β = 1, and check
that dδˆL=0/dβ < 0, as required.
C.3 Proof of Proposition 3
Firstly, if β = θ/2, for all δ, concentrated profits pii(x) depend only on each firm i’s own R&D variable
xi (Property 1), in which case the cooperative and non-cooperative games coincide. Secondly, if δ = 0,
for all β, we have r(x1) + r(x2) = s(x) (Property 2), and solving the cooperative game is equivalent
to solving the delegated game (Proposition 1). Thirdly, if β = θ/2 and δ = 0, the laboratory earns
no benefits (Proposition 2). By considering all three cases together, we conclude that the cooperative,
non-cooperative, and delegated R&D games yield identical outcomes at the non-externalities point
(θ/2, 0).
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D Proof of Lemmas
We first establish how indirect externalities impact optimal outcomes in the delegated R&D game.
This will be useful for the proofs of Lemmas 1− 3, which follow.
Lemma D-1 (R&D) dxd/dδ > 0.
Differentiating (27) with respect to δ gives:
dxd
dδ
= 2αb (1 + β) (2 + θ)2/Γ24, (62)
which is positive.
Lemma D-2 (Profits) dpid/dδ > 0.
We consider δ > δL=0 and δ ≤ δL=0 in turn.
(δ ≥ δL=0) By Propositions 1 and 2:
pid = Λ/2. (63)
Recalling that the laboratory’s cost are given by (8), aggregate benefits by (14), and using the












which is unambiguously positive given that xd > 0.
(δ ≤ δL=0) Assume that pi









and look for a contradiction. To do that, recall from Proposition 1 that the laboratory maximizes








Moreover, recalling that the laboratory’s cost are given by (8) and aggregate benefits by (14),
by using the envelope theorem we obtain dΛ/dδ = (xd)2, which is unambiguously positive given















by transitivity. Inequality (68) contradicts the result that pid ≤ Λ/2 for all δ ≤ δL=0, as established
by Propositions 1 and 2. Hence dpid/dδ > 0.
Lemma D-3 (Welfare) dwd/dδ > 0.
Welfare is defined as the sum of firms’ profits and consumer surplus. It has been established above
that profits pid are increasing in δ. Here we turn to consumer surplus by investigating how qi(x
d) and
pi(x
d) vary with δ.
(qi(x
d)) Differentiating the Cournot-Nash symmetric equilibrium output (16) evaluated at xd = (xd, xd),





(2 + θ) (1 + β)xd
Γ4
. (69)
As the denominator of (69), as well as the other parameters of the model and xd are positive, it
follows that (69) is also positive.
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(pi(x
d)) Differentiating the inverse demand function (1) evaluated at the symmetric equilibrium xd =





b(1 + θ) (2 + θ) (1 + β)xd
Γ4
, (70)
which is negative since xd and Γ4 are positive.
Taking (69) and (70) together means that the consumer surplus is increasing in δ. The fact that firms’
profits are also increasing in δ (Lemma D-2) completes the proof.
D.1 Proof of Lemma 1
D.1.1 Equal Delegated and Cooperative R&D Frontier δxd=xc
As xd is monotone increasing in δ (Lemma D-1) and xc is invariant with δ, it follows that if there exists
a value of δ for which xd = xc, it is unique. Moreover, for δ = 0, (i) the costs of R&D are the same for
the laboratory in the delegated R&D and for both firms in the cooperative game (see Property 2), and
(ii) solving the delegated game for xd is equivalent to solving the cooperative game for xc (because of
Proposition 1). Hence, xd = xc for δ = 0. Making use of that result, Lemma D-1, that xc does not
vary with δ and Proposition 2 gives Lemma 1-(i).
D.1.2 Equal Delegated and Non-Cooperative R&D Frontier δxd=xn
Using (22) and (27) we define:
∆(δ) ≡ xd − xn. (71)
(β = θ/2)
Proposition 3 establishes that ∆(0) = 0.
(β < θ/2)
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Claim A: ∆(δ) < 0. Section D.1.1 establishes that xd = xc for δ = 0. Next, we know from
d’Aspremont and Jacquemin (1988) that xc < xn for β ∈ [0, θ/2) and all values of δ. Claim A
follows by transitivity.
Claim B: ∆(δ) > 0 along δL=0. Recall from (61) that δL=0 = δˇL=0 > 0 for β < θ/2. Then
evaluating (71) at δ = δˇL=0, and equating to 0 gives 7 roots (γ = 0, θ = ±2, α = 0, β = θ/2, β =
1, b = 0), none of which is admissible. Therefore, ∆(δˇL=0) does not change sign over this range
of β. It is straightforward to check that claim B holds by computing ∆(δˇL=0) at, say, β = 0 and
any admissible values for the other parameters, and obtaining a positive value.
(β > θ/2)
Claim C: ∆(δ) > 0 for δ = 0. Recall that xd = xc for δ = 0, as established in Section D.1.1.
Then note that xc > xn for β ∈ (θ/2, 1] from d’Aspremont and Jacquemin (1988), all δ. Claim C
follows by transitivity.
Claim D: ∆(δ) < 0 along δL=0. Recall from (61) that δL=0 = δˆL=0 < 0 for β > θ/2, evaluate (71)
at δ = δˆL=0, and equating to 0 gives 7 roots (γ = 0, θ = ±2, α = 0, β = θ/2, β = 2/θ, b = 0.),
none of which is admissible. Therefore, ∆(δˆL=0) does not change sign over the relevant range of
β. It is straightforward to check that ∆(δˆL=0) is negative by evaluating it at, say, β = 1 and any
value for other parameters. Hence claim D is true.
Recall how δL=0 is constructed in (61). Using claims A to D, that x
d is continuous and monotone
increasing in δ (Lemma D-1) while xn does not vary with δ, means there exists a unique δ ≡ δxd=xn
such that xd >=
<
xn if and only if δ >=
<
δxd=xn , with δxd=xn as in Lemma 1-(ii).
D.2 Proof of Lemma 2
D.2.1 Equal Delegated and Cooperative Profits Frontier δpid=pic
(β = θ/2)
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We know from Proposition 3 that pid = pic for δ = 0 (the no-externalities case).
Now we consider β < θ/2, for which δL=0 > 0, and β > θ/2, for which δL=0 < 0.
(β < θ/2)





because the laboratory appropriates a share of maximized aggregate benefits as L > 0 for δ =





from the specification of the cooperative R&D game. Putting (72) and (73) together gives pid < pic
for δ = 0.





from Propositions 1 and 2 because firms earn all maximized aggregate benefits as L = 0 for





because of (73) and Λ|δ=0 < Λ|δ=δL=0 as a result of (64). Putting (74) and (75) together means
claim B holds.
(β > θ/2)











from the specification of the cooperative R&D game. Claim C follows from (76) and (77).
Claim D: δL=0 < 0 for β > θ/2. That claim follows directly from Proposition 2.
Given claims A to D, that pid is continuous and monotone increasing in δ (Lemma D-2) means




pic if and only if δ >=
<
δpid=pic , with δpid=pic as
in Lemma 2-(i).
D.2.2 Equal Delegated and Non-Cooperative Profits Frontier δpid=pin
(β = θ/2)
We know from Proposition 3 that pid = pin for δ = 0.
Now we consider β < θ/2, for which δL=0 > 0, and β > θ/2, for which δL=0 < 0. In both cases, we
make use of δxd=xn as defined in Lemma 1. Note that δxd=xn is identical to δxˇj=xˆj=0, for all β. Indeed,





which is the same as (55). The other non-admissible roots to xd−xn = 0 are α = 0, θ = −2, and b = 0.
(β < θ/2)
Claim A: pid < pin for δ = δxd=xn . To prove claim A note that as δ = δxˇj=xˆj=0 = δxd=xn , it
follows that pid = Λ − Π({i}) from Proposition 2,25 with Π({i}) = Πˇ({i}) = Πˆ({i}) because of
the definition of δxˇj=xˆj=0. Using the latter and (23) we define:
∆˜(δ) = pid − pin. (78)
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As the roots to ∆˜(δxd=xn) = 0 (γ = 0, α = 0, β = θ/2, β = 2/θ) are not admissible, ∆˜(δxd=xn)
does not change sign. It suffices to evaluate (78) at, say, β = 0, to check that claim A is valid.
Claim B: pid > pin for δ = δpid=pic . We know that pi
d = pic along δpid=pic by definition, while pi
c > pin
for β < θ/2 and any δ from d’Aspremont and Jacquemin (1988). Therefore, by transitivity claim
B is true.
(β > θ/2)
Claim C: pid < pin for δ = δxd=xn . Recall from (2) that the unit costs of production are equal under





n), for i = 1, 2, along δxd=xn . It follows that gross concentrated profits (i.e., before




i = 1, 2. Moreover, we know from Lemma 1-(ii) that δL=0 < δxd=xn < 0. The first inequality
sign means that the laboratory exactly breaks even along δxd=xn because of Proposition 2. This
implies that firms’ symmetric transfer payments exactly cover the laboratory’s costs, that is
td1(x
d) + td2(x
d) = s(xd). The second inequality means indirect externalities are negative along
δxd=xn , because of Property 2. This implies that the laboratory’s R&D costs are strictly greater













n)− r(xni ), (80)
i = 1, 2. Inequality (80) says that claim C, which refers to net profits, is true.
Claim D: pid > pin for δ = 0. In the absence of indirect externalities, we have s(x) = r(x1)+r(x2).
In that case, from Proposition 1, we know that solving the delegated game for xd is equivalent
to solving the cooperative game for xc. Then, from Proposition 2, because δ = 0 > δL=0 implies
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that the laboratory exactly breaks even, we have pid = pic. As pic is always greater than pin, from
d’Aspremont and Jacquemin (1988), claim D follows by transitivity.
Given claims A to D, that pid is continuous and monotone increasing in δ from Lemma D-2, and pin is




pin if and only if δ >=
<
δpid=pin ,
with δpid=pin as in Lemma 2-(ii).
D.3 Proof of Lemma 3
D.3.1 Equal Delegated and Cooperative Welfare Frontier δwd=wc
As wd is monotone increasing in δ (Lemma D-3), and wc does not vary with δ, it follows that if
there exists a value of δ such that wd = wc, it is unique. Moreover, for δ = 0, we know (i) the
laboratory’s costs in the delegated game are equal to both firms’ total R&D costs in the cooperative
game (Property 2), and (ii) solving the delegated game for xd is equivalent to solving the delegated





c), i = 1, 2. Recalling that wd is continuous and monotone
increasing in δ, whereas wc is invariant with δ, gives Lemma 3-(i).
D.3.2 Equal Delegated and Non-Cooperative Welfare Frontier δwd=wn
(β = θ/2)
We know from Proposition 3 that wd = wn for δ = 0.
Now we turn to the other values of β.
i) We compare consumer surpluses and gross concentrated profits (i.e., before R&D costs), in the
delegated and non-cooperative games along δxd=xn , and show they are the same. To see that, recall
that xd = xn along δxd=xn , by definition. Therefore production costs, together with quantities
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n), i = 1, 2. It follows that firms’ gross profits and consumer surpluses are the same
in the delegated and non-cooperative R&D games along δxd=xn .
ii) We show that the sign of the difference between total R&D costs in the delegated and non-





0 if and only if δ >=
<





0 if and only if β <=
>










for all x1, x2 > 0. Hence, (81) means that along δxd=xn , the laboratory’s costs are less than (equal
to, greater than) firms’ total in-house R&D costs if and only if β is less than (equal to, greater
than) θ/2.













We now use (82) to establish the existence of δwd=wn for β < θ/2, and β > θ/2 respectively.
(β < θ/2)
Claim A: wd > wn along δxd=xn . This claim follows from (82). Moreover δxd=xn < δpid=pin from
Lemma 2-(ii), for β < θ/2.
Claim B: wd < wn for δ = 0. Recall that wc = wd for δ = 0 by Proposition 1, and wc < wn for
β < θ/2 from d’Aspremont and Jacquemin (1988). Claim B follows by transitivity.
(β > θ/2)
Claim C: wd < wn along δxd=xn , for β > θ/2. The proof of claim C follows directly from (82).
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Claim D: wd > wn for δ = δpid=pin . On the firms’ side, pi
d = pin on δpid=pin by definition. On
the consumers’ side, because δpid=pin > δxd=xn from Lemma 2-(ii), we obtain x
d > xn, and
consequently ci(x
d) < ci(x




n), i = 1, 2, on δpid=pin .
On the laboratory’s side, we know that δpid=pin > δL=0 from Lemma 2-(ii) in the case of positive
direct externalities, which implies that L = 0 from Proposition 2. As firms and consumers are
better-off in the delegated R&D game than in the non-cooperative one, while the laboratory earns
zero benefits in either game, means that claim D is true.
Using claims A to D, that wd is continuous and monotone increasing in δ (Lemma D-3), while




wn if and only if
δ >=
<
δwd=wn , with δwd=wn as in Lemma 3-(ii).
E Comparison of p¯ic with pic, pin, pid
Recall that we denote by p¯ic the profits each firm earns by cooperating in R&D with the rival firm
when the R&D costs are the same as in the delegated R&D game, and δ ≥ 0.
Note first that p¯ic = Λ/2 = pid if δ ≥ δL=0, and that p¯i
c = Λ/2 > pid if δ < δL=0, by construction of
the alternative cooperative R&D game. This implies that the profit frontiers for the comparison of pic
with pic and pin coincide with the profit frontiers for the comparison of pid with pic and pin at all points
on δL=0 or above δL=0 in the plane of externalities (β, δ).
It thus remains to compare the new profit frontiers δp¯ic=pic and δp¯ic=pin with the frontiers defined
in Lemmas 1, 2 and 3, that were demonstrated to lie strictly below δL=0. The only candidates are
δxd=xc , δxd=xn , δpid=pic , δpid=pin , δwd=wc , δwd=wn for β < θ/2. To do that, note first that p¯i
c = Λ/2 by
construction, and recall that dΛ/dδ > 0, to conclude that dp¯ic/dδ > 0. Then consider the frontiers
δp¯ic=pic and δp¯ic=pin in turn, as follows.
57
(δp¯ic=pic) Recall that p¯i
c = pic for δ = 0, by construction. As p¯ic is strictly monotone in δ, whereas
pic does not depend on δ, we obtain δp¯ic=pic = 0. It follows that δp¯ic=pic = δxd=xc = δwd=wc , all
β < θ/2.
(δp¯ic=pin) As pi
n < pic and pic = p¯ic = Λ/2 for δ = 0, the monotonicity of p¯ic in δ implies that p¯ic cannot
be equal to pin if δ is non-negative. It follows that δp¯ic=pin does not exist if δ ≥ 0, all β < θ/2.
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F. Figures
All four ﬁgures are drawn for a = 1, b = 1, c = 3/4, γ = 2, θ = 1. Figures 1, 2, 3
include a reference to the following results by d’Aspremont and Jacquemin (1988): (i)
xc >=
<
xn if and only if β >=
<
θ/2; (ii) πc = πn at β = θ/2, otherwise πc > πn; and (iii)
wc >=
<
















Figure 1: (R&D outcomes): xd >=
<
xn if and only if δ >=
<
δxd=xn , and xd >=< x
c if and


















Figure 2: (Firms’ proﬁts): πd >=
<
πn if and only if δ >=
<
δπd=πn , and πd >=< π


















Figure 3: (Social welfare): wd >=
<
wn if and only if δ >=
<
δwd=wn , and wd >=< w
c if and













Figure 4: (Delegation dominance): the shaded area represents the set of points (β, δ)
for which the delegated R&D game is a Pareto optimal organizational form of R&D, and
the laboratory earns positive beneﬁts.
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Notes
1The National Science Foundation (2006) uses the term “contract R&D” to denote a transaction with external parties
involving R&D payments or income, regardless of the actual legal form of the transaction. The quoted figures do not
include contract R&D expenses by U.S. companies that do not perform internal R&D, or that contract out R&D to
companies located overseas.
2For details on these contracts, and other examples, see: www.recap.com/bday.nsf.
3For example, Kamien, Tauman and Zang (1988) examine the case of a superior product which is licensed to producers
of an inferior substitute through a fixed fee. Kamien, Oren and Tauman (1992b) compare alternative licensing strategies,
namely a fixed fee, a per unit royalty, and the auctioning of a fixed number of licenses.
4For instance, Kamien et al. (1992a) consider spillovers on the input side of the R&D stage, Suzumura (1992) introduces
a second-best welfare criterion, Motta (1992) and Rosenkranz (1995) consider quality-improving R&D, Vonortas (1994)
distinguishes between generic research and commercial development, Poyago-Theotoky (1999) and Kamien and Zang
(2000) endogeneize spillovers, and Hinloopen (2000) introduces Bertrand competition on the final market with more than
two firms.
5See Martin (2001) for a critical overview of that literature.
6In the business literature, the outsourcing of new technological knowledge – under conditions stipulated in a con-
tract agreed beforehand – is clearly distinguished from situations in which firms license existing technological knowledge
(Howells, James and Malik 2003, for example).
7This terminology is similar to what Laffont and Martimort (1997) call “type 1” (indirect) and “type 2” (direct)
externalities.
8By contrast, in an intrinsic common agency model the agent is forced to contract with all principals, or none of them.
9By comparison, in a private common agency set-up a principal may contract only on the quantities it specifically
receives from the agent.
10This is done as in the present paper, but for more general functional forms, by associating to the common agency
setting a transferable utility cooperative game (see Appendix C, which builds on Laussel and Le Breton (2001)). The
characteristic function of this cooperative game is defined as the maximum level of joint profits as obtained by the
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laboratory and any subset of contracting firms (that is either none, or only one of the two firms, or both of them). Then
it is proved that the laboratory appropriates some non-zero share of joint profits if the characteristic function reflects
substitutabilities in R&D dimensions (which may result from negative externalities of the direct and/or indirect kinds).
Alternatively, the laboratory breaks-even if the characteristic function reflects complementarities in R&D dimensions.
The proposed sufficient conditions are shown to be satisfied by many specifications used in a sample of papers on the
industrial organization of R&D.
11Aghion and Tirole (1994) and Ambec and Poitevin (2001) differ fundamentally in their theoretical use of the non-
deterministic R&D assumption. While Aghion and Tirole (1994) emphasize the non-contractibility of the uncertain R&D
outcome, Ambec and Poitevin (2001) stress an informational problem as attached to the risky nature of R&D tasks.
12In d’Aspremont and Jacquemin (1988), and in the cooperative R&D model of the present paper, the two firms are
subject to “ex-ante equal treatment”, in the terminology introduced by Leahy and Neary (2005). This means that the
symmetric firms are assumed to invest equally in R&D when they cooperate, “a natural starting point” (p. 384) when
side-payments between firms are ruled out.
13This alternative set-up constitutes an example in a class of principal-agent models surveyed by Gal-Or (1997, Section
3, pp. 241-248). In these models, contracts are observable, several principals compete in the market-place, and each of
them delegates the production of an input to its own specific agent.
14Most papers refer in particular to the US National Cooperative Research Act (NCRA) of 1984, and its 1993 subsequent
amendment, which is usually described as a means to reduce legal disincentives to participate in contractual R&D
agreements. This act gives firms the possibility of limiting antitrust analysis to the rule of reason (in lieu of the per se
illegality rule) on all “properly defined, relevant research and development markets”. It also limits antitrust recoveries
against registered agreements to lower damages if the terms of the submitted agreement are found to violate the law.
According to Martin (1996, p. 270) it leads antitrust authorities to adopt a “permissive attitude” (added emphasis).
More recently, Amir et al. (2003) extend this comment to other geographical areas by emphasizing that “a permissive
antitrust attitude towards R&D cooperation has been the norm in Europe and Japan early on” (p. 184).
15This state of affairs leads Majewski (2004) to question the cooperative character of these cases: “the fact that a
significant subset of observations organizes their collaboration as a nexus of arms-length contracts raises the question of
what ‘collaborative R&D’ means” (p. 20). We see this as an encouragement to the examination of delegated R&D set-ups
in complement to existing comparisons of cooperative versus non-cooperative R&D set-ups.
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16Sinclair-Desgagne´ (2001) also mentions, in an example, that R&D contracts could be analyzed in a common agency
set-up where principals condition their payments to the agent on the quantities received by other principals.
17Dobler and Burt (1996, p. 416) observe that “R&D services normally are purchased through one of the two methods
of compensation: a fixed price for a level of effort (e.g., fifty days) or a cost plus fixed or award fee”.
18A Nash equilibrium in a common agency game is coalition-proof if it is robust to credible threats of deviations by some
subsets of the principals (see Bernheim, Peleg and Whinston (1987) for a formal definition). When there are only two
principals, as in our delegated R&D model, a coalition-proof equilibrium is Pareto-efficient among principals (Bernheim
and Whinston 1986b, p. 16 footnote 11).
19For more on this see Kirchsteiger and Prat (2001, footnote 7 on p. 354), and Martimort (2005, pp. 19-20).
20In this example, the numerical values are obtained from the algebraic expressions displayed in the proof of Proposi-
tion 2.
21It is straightforward to compare the asymmetric equilibrium R&D levels x¯1 = 0 and x¯2 ≡ x¯
d > 0 (say), as obtained
for all δ < δ¯, with the symmetric interior solution xd1 = x
d
2 = x
d to the joint-profit maximizing problem (14) when δ = δ¯.
From the equilibrium expressions computed in the appendix (see sections A.2 and C.1) one finds x¯d = 2xd on the frontier
δ¯. Next, continuity of Λ (x) in δ implies that p¯id = pid on the frontier δ¯. This implies that one may focus on the consumer
surplus to compare total welfare with an interior solution or a corner solution on δ¯. For all β and θ less than 1, simple
algebra leads to w¯d > wd (with an equality sign if β = 1 or θ = 1), again on the frontier δ¯.
22More formally, r(xi) =
γ
2
(1 + β)x2i , in the cooperative and non-cooperative in-house R&D games. In this case, Amir
(2000) demonstrates that d’Aspremont and Jacquemin (1988), in which x is a vector of R&D outcomes, and Kamien et al.
(1992a), in which x describes R&D investments, yield the same effective cost-reducing outcomes. We let the laboratory’s
cost function be s(x) = γ
2
(1 + β)(x21 + x
2
2)− δx1x2.
23A first step towards the generalization of the delegated R&D model to more than two firms is easily obtained by
applying two recent results by Billete de Villemeur and Versaevel (2003). They establish sufficient conditions for Π(S),
as defined in (43), with S ∈ 2N and #N ≥ 2, to be either strictly subadditive or convex (and thus for the laboratory to
earn positive benefits or to exactly break even, respectively). However, Π(S) should be strongly subbadditive to obtain
pid = Λ−Π(N\{i}), for all i, in all TSPNE. The strong subadditivity property (see Laussel and Le Breton (2001, p. 104)
for a formal definition) is stronger than the strict additivity property used in this paper. The two properties coincide for
#N = 2 only.
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24The conjecture that an agent in charge of R&D activities may have no superior information about project returns
before acting dates back from Holmstrom (1989), who sees it as a ”reasonable assumption if we are at the initial stages of
a research undertaking” (p. 310). Interestingly, this falls in line with the specifications of a theoretical paper on common
agency by Laussel and Le Breton (1998), who introduce a random parameter in the agent’s cost function which is not
realized at the contracting stage. In this setting, the laboratory’s cost would become µs(x), where µ is a positive random
variable. The laboratory would not know the realization of µ before accepting or refusing the firms’ contracts (that is,
strategies ti(x) in our notation, i = 1, 2), but would learn it before producing R&D services (that is, x).
25Lemma 1-(ii) implies that δxˇj=xˆj=0 = δxd=xn < δL=0.
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